Abstract
The main statements of the recommendations of the American College of Rheumatology and the Vasculitis Foundation on the treatment of patients with systemic vasculitis of large vessels, published in August 2021, are discussed. As a result of a detailed review of current data, a group of experts proposed 22 recommendations and 2 ungraded position statements for giant cell arteritis (GCA), as well as 20 recommendations and 1 ungraded position statement for Takayasu arteritis (AT), on the basis of which algorithms for the treatment of patients with these diseases are presented. An expansion of the value of genetically engineered biological therapy, primarily tocilizumab in GCA and tumour necrosis factor alpha inhibitors in AT, has been recorded. The new recommendations should not be considered as final standards, but are intended to become the basis for choosing a personalized treatment strategy for patients with large vessels vasculitis and serve as a starting point for further research.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have